<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36922834</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>The era of cryptic exons: implications for ALS-FTD.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-023-00608-5</ELocationID><Abstract><AbstractText>TDP-43 is an RNA-binding protein with a crucial nuclear role in splicing, and mislocalises from the nucleus to the cytoplasm in a range of neurodegenerative disorders. TDP-43 proteinopathy spans a spectrum of incurable, heterogeneous, and increasingly prevalent neurodegenerative diseases, including the amyotrophic lateral sclerosis and frontotemporal dementia disease spectrum and a significant fraction of Alzheimer's disease. There are currently no directed disease-modifying therapies for TDP-43 proteinopathies, and no way to distinguish who is affected before death. It is now clear that TDP-43 proteinopathy leads to a number of molecular changes, including the de-repression and inclusion of cryptic exons. Importantly, some of these cryptic exons lead to the loss of crucial neuronal proteins and have been shown to be key pathogenic players in disease pathogenesis (e.g., STMN2), as well as being able to modify disease progression (e.g., UNC13A). Thus, these aberrant splicing events make promising novel therapeutic targets to restore functional gene expression. Moreover, presence of these cryptic exons is highly specific to patients and areas of the brain affected by TDP-43 proteinopathy, offering the potential to develop biomarkers for early detection and stratification of patients. In summary, the discovery of cryptic exons gives hope for novel diagnostics and therapeutics on the horizon for TDP-43 proteinopathies.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Puja R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL Queen Square Motor Neuron Disease Centre, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Anna-Leigh</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL Queen Square Motor Neuron Disease Centre, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7554-1632</Identifier><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL Queen Square Motor Neuron Disease Centre, London, WC1N 3BG, UK. p.fratta@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>102186/B/13/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008606/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S006508/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U54 NS123743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Cryptic exons</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">STMN2</Keyword><Keyword MajorTopicYN="N">Splicing</Keyword><Keyword MajorTopicYN="N">TDP-43 proteinopathies</Keyword><Keyword MajorTopicYN="N">Therapeutics</Keyword><Keyword MajorTopicYN="N">UNC13A</Keyword></KeywordList><CoiStatement>A patent application related to this work has been filed. The technology described in this work has been protected in the patent PCT/EP2021/084908 and UK patent 2117758.9 (patent applicant, UCL Business Ltd. and NIH; status pending), in which AL-B, MEW, and PF are named as inventors. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36922834</ArticleId><ArticleId IdType="pmc">PMC10018954</ArticleId><ArticleId IdType="doi">10.1186/s13024-023-00608-5</ArticleId><ArticleId IdType="pii">10.1186/s13024-023-00608-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 2007;1184:284&#x2013;294. doi: 10.1016/j.brainres.2007.09.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.048</ArticleId><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, Silsby M, Menon P, van den Bos M, Halliday GM, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2020;92:86&#x2013;95. doi: 10.1136/jnnp-2020-322983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, Taylor JP, Kretzschmar HA, Kimonis VE, Forman MS. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol. 2007;66:152&#x2013;157. doi: 10.1097/nen.0b013e31803020b9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31803020b9</ArticleId><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisse K, Volkening K, Leystra-Lantz C, Welch I, Hill T, Strong MJ. Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res. 2009;1249:202&#x2013;211. doi: 10.1016/j.brainres.2008.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2008.10.021</ArticleId><ArticleId IdType="pubmed">19046946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiesner D, Tar L, Linkus B, Chandrasekar A, Olde Heuvel F, Dupuis L, Tsao W, Wong PC, Ludolph A, Roselli F. Reversible induction of TDP-43 granules in cortical neurons after traumatic injury. Exp Neurol. 2018;299:15&#x2013;25. doi: 10.1016/j.expneurol.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.09.011</ArticleId><ArticleId IdType="pubmed">28941811</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HK, Lee YC, Huang CY, Liliang PC, Lu K, Chen HJ, Li YC, Tsai KJ. Traumatic brain injury causes frontotemporal dementia and TDP-43 proteolysis. Neuroscience. 2015;300:94&#x2013;103. doi: 10.1016/j.neuroscience.2015.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.05.013</ArticleId><ArticleId IdType="pubmed">25982564</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F, Hu M, Zhang J, Hashem J, Chen C. TDP-43 drives synaptic and cognitive deterioration following traumatic brain injury. Acta Neuropathol. 2022;144:187&#x2013;210. doi: 10.1007/s00401-022-02449-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02449-w</ArticleId><ArticleId IdType="pmc">PMC9945325</ArticleId><ArticleId IdType="pubmed">35713704</ArticleId></ArticleIdList></Reference><Reference><Citation>del Aguila MA, Longstreth WT, Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60:813&#x2013;819. doi: 10.1212/01.WNL.0000049472.47709.3B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000049472.47709.3B</ArticleId><ArticleId IdType="pubmed">12629239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586&#x2013;590. doi: 10.1212/01.wnl.0000172911.39167.b6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000172911.39167.b6</ArticleId><ArticleId IdType="pubmed">16116120</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995&#x2013;1007. doi: 10.1016/S1474-4422(10)70195-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70195-2</ArticleId><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650&#x2013;655. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276:36337&#x2013;36343. doi: 10.1074/jbc.M104236200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104236200</ArticleId><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, De Conti L, Stuani C, Romano M, Baralle M, Baralle F. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J. 2010;277:2268&#x2013;2281. doi: 10.1111/j.1742-4658.2010.07643.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2010.07643.x</ArticleId><ArticleId IdType="pubmed">20423455</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Jansen-West KR, Lee WC, Gendron TF, Zhang YJ, Xu YF, Gass J, Stuani C, Stetler C, Rademakers R, et al. Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc Natl Acad Sci U S A. 2012;109:21510&#x2013;21515. doi: 10.1073/pnas.1211577110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1211577110</ArticleId><ArticleId IdType="pmc">PMC3535614</ArticleId><ArticleId IdType="pubmed">23236149</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiesel FC, Weber SS, Supper J, Zell A, Kahle PJ. TDP-43 regulates global translational yield by splicing of exon junction complex component SKAR. Nucleic Acids Res. 2012;40:2668&#x2013;2682. doi: 10.1093/nar/gkr1082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr1082</ArticleId><ArticleId IdType="pmc">PMC3315294</ArticleId><ArticleId IdType="pubmed">22121224</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga A, Ishihara T, Miyashita A, Kuwabara M, Kato T, Watanabe N, Yamahira A, Kondo C, Yokoseki A, Takahashi M, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS One. 2012;7:e43120. doi: 10.1371/journal.pone.0043120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043120</ArticleId><ArticleId IdType="pmc">PMC3416794</ArticleId><ArticleId IdType="pubmed">22900096</ArticleId></ArticleIdList></Reference><Reference><Citation>Prpar Mihevc S, Baralle M, Buratti E, Rogelj B. TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins. Sci Rep. 2016;6:33996. doi: 10.1038/srep33996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep33996</ArticleId><ArticleId IdType="pmc">PMC5036055</ArticleId><ArticleId IdType="pubmed">27665936</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohagheghi F, Prudencio M, Stuani C, Cook C, Jansen-West K, Dickson DW, Petrucelli L, Buratti E. TDP-43 functions within a network of hnRNP proteins to inhibit the production of a truncated human SORT1 receptor. Hum Mol Genet. 2016;25:534&#x2013;545. doi: 10.1093/hmg/ddv491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv491</ArticleId><ArticleId IdType="pmc">PMC4731020</ArticleId><ArticleId IdType="pubmed">26614389</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Roczniak-Ferguson A, Ferguson SM. Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis. Life Sci Alliance. 2019;2:e201900358. doi: 10.26508/lsa.201900358.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.201900358</ArticleId><ArticleId IdType="pmc">PMC6749094</ArticleId><ArticleId IdType="pubmed">31527135</ArticleId></ArticleIdList></Reference><Reference><Citation>Susnjar U, Skrabar N, Brown AL, Abbassi Y, Phatnani H, Consortium NA, Cortese A, Cereda C, Bugiardini E, Cardani R, et al. Cell environment shapes TDP-43 function with implications in neuronal and muscle disease. Commun Biol. 2022;5:314. doi: 10.1038/s42003-022-03253-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03253-8</ArticleId><ArticleId IdType="pmc">PMC8983780</ArticleId><ArticleId IdType="pubmed">35383280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J, Hortobagyi T, Nishimura AL, Zupunski V, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14:452&#x2013;458. doi: 10.1038/nn.2778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2778</ArticleId><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14:459&#x2013;468. doi: 10.1038/nn.2779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2779</ArticleId><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Bell W, LaClair KD, Ling JP, Han H, Kageyama Y, Pletnikova O, Troncoso JC, Wong PC, Chen LL. Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathol. 2017;133:923&#x2013;931. doi: 10.1007/s00401-017-1701-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1701-2</ArticleId><ArticleId IdType="pmc">PMC5444385</ArticleId><ArticleId IdType="pubmed">28332094</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres P, Ramirez-Nunez O, Romero-Guevara R, Bares G, Granado-Serrano AB, Ayala V, Boada J, Fontdevila L, Povedano M, Sanchis D, et al. Cryptic exon splicing function of TARDBP interacts with autophagy in nervous tissue. Autophagy. 2018;14:1398&#x2013;1403. doi: 10.1080/15548627.2018.1474311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2018.1474311</ArticleId><ArticleId IdType="pmc">PMC6103657</ArticleId><ArticleId IdType="pubmed">29912613</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, McMahon MA, Beccari MS, Artates JW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Humphrey J, Pickles S, Brown AL, Hill SE, Kachergus JM, Shi J, Heckman MG, Spiegel MR, Cook C, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020;130:6080&#x2013;6092. doi: 10.1172/JCI139741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI139741</ArticleId><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, Bampton A, Lee FCY, Masino L, Qi YA, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, Briner A, Rodriguez CM, Guo C, Akiyama T, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603:124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Britson KA, Ling JP, Braunstein KE, Montagne JM, Kastenschmidt JM, Wilson A, Ikenaga C, Tsao W, Pinal-Fernandez I, Russell KA, et al. Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Sci Transl Med. 2022;14:eabi9196. doi: 10.1126/scitranslmed.abi9196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi9196</ArticleId><ArticleId IdType="pmc">PMC9118725</ArticleId><ArticleId IdType="pubmed">35044790</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong YH, Ling JP, Lin SZ, Donde AN, Braunstein KE, Majounie E, Traynor BJ, LaClair KD, Lloyd TE, Wong PC. Tdp-43 cryptic exons are highly variable between cell types. Mol Neurodegener. 2017;12:13. doi: 10.1186/s13024-016-0144-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0144-x</ArticleId><ArticleId IdType="pmc">PMC5289002</ArticleId><ArticleId IdType="pubmed">28153034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes. Nat Rev Mol Cell Biol. 2015;16:665&#x2013;677. doi: 10.1038/nrm4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm4063</ArticleId><ArticleId IdType="pubmed">26397022</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB. Loss of nuclear TDP-43 is associated with Decondensation of LINE retrotransposons. Cell Rep. 2019;27:1409&#x2013;1421. doi: 10.1016/j.celrep.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.04.003</ArticleId><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, Lemmens R, Schelhaas HJ, Groen EJ, Huisman MH, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41:1083&#x2013;1087. doi: 10.1038/ng.442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.442</ArticleId><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin I, Rosenmund C, Sudhof TC, Brose N. Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. Nature. 1999;400:457&#x2013;461. doi: 10.1038/22768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/22768</ArticleId><ArticleId IdType="pubmed">10440375</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel AG, Selcen D, Shen XM, Milone M, Harper CM. Loss of MUNC13-1 function causes microcephaly, cortical hyperexcitability, and fatal myasthenia. Neurol Genet. 2016;2:e105. doi: 10.1212/NXG.0000000000000105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000105</ArticleId><ArticleId IdType="pmc">PMC5017540</ArticleId><ArticleId IdType="pubmed">27648472</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PW, van Rheenen W, Koppers M, Pasterkamp RJ, van Es MA, Schelhaas HJ, de Visser M, Robberecht W, Van Damme P, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(630):e633&#x2013;e638.</Citation><ArticleIdList><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Mora G, Restagno G, Brunetti M, Ossola I, Barberis M, Ferrucci L, Canosa A, Manera U, Moglia C, et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiol Aging. 2013;34(357):e351&#x2013;e355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483408</ArticleId><ArticleId IdType="pubmed">22921269</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Taboada JM, Lopez-Lopez A, Salvado M, Lorenzo L, Garcia C, Mahy N, Rodriguez MJ, Gamez J. UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. J Neurol. 2015;262:2285&#x2013;2292. doi: 10.1007/s00415-015-7843-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7843-z</ArticleId><ArticleId IdType="pubmed">26162714</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaastra B, Shatunov A, Pulit S, Jones AR, Sproviero W, Gillett A, Chen Z, Kirby J, Fogh I, Powell JF, et al. Rare genetic variation in UNC13A may modify survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:593&#x2013;599. doi: 10.1080/21678421.2016.1213852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1213852</ArticleId><ArticleId IdType="pmc">PMC5125285</ArticleId><ArticleId IdType="pubmed">27584932</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Jiang H, Wang F, Li S, Wu C, Bao J, Zhu Y, Xu Z, Liu B, Ren H, Yang X. UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis. Neurol Sci. 2019;40:2293&#x2013;2302. doi: 10.1007/s10072-019-03951-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03951-y</ArticleId><ArticleId IdType="pubmed">31201598</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K, Baer GM, Elman L, McCluskey L, Hennessy L, Ferraro PM, Lee EB, Lee VMY, Trojanowski JQ, Van Deerlin VM, et al. UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2019;73:190&#x2013;199. doi: 10.1016/j.neurobiolaging.2018.09.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.09.031</ArticleId><ArticleId IdType="pmc">PMC6251755</ArticleId><ArticleId IdType="pubmed">30368160</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HHG, Westeneng HJ, van der Burgh HK, van Es MA, Bakker LA, van Veenhuijzen K, van Eijk KR, van Eijk RPA, Veldink JH, van den Berg LH. The distinct traits of the UNC13A polymorphism in amyotrophic lateral sclerosis. Ann Neurol. 2020;88:796&#x2013;806. doi: 10.1002/ana.25841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25841</ArticleId><ArticleId IdType="pmc">PMC7540607</ArticleId><ArticleId IdType="pubmed">32627229</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, Schultz D, Benatar M, Rogers ML. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88:1137&#x2013;1143. doi: 10.1212/WNL.0000000000003741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265:510&#x2013;521. doi: 10.1007/s00415-017-8730-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8730-6</ArticleId><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, Tumani H, von Arnim CAF, Dorst J, Feneberg E, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:157&#x2013;164. doi: 10.1136/jnnp-2018-318704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Curr Opin Neurol. 2005;18:698&#x2013;705. doi: 10.1097/01.wco.0000186842.51129.cb.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wco.0000186842.51129.cb</ArticleId><ArticleId IdType="pubmed">16280682</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh W, Pan W, Gawad C, Fan HC, Kerchner GA, Wyss-Coray T, Blumenfeld YJ, El-Sayed YY, Quake SR. Noninvasive in vivo monitoring of tissue-specific global gene expression in humans. Proc Natl Acad Sci U S A. 2014;111:7361&#x2013;7366. doi: 10.1073/pnas.1405528111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1405528111</ArticleId><ArticleId IdType="pmc">PMC4034220</ArticleId><ArticleId IdType="pubmed">24799715</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, Cruts M, Van Broeckhoven C, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PE, Bieniek KF, Gendron TF, Caulfield T, Lin WL, Dejesus-Hernandez M, van Blitterswijk MM, Jansen-West K, Paul JW, 3rd, Rademakers R, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646. doi: 10.1016/j.neuron.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaai7866. doi: 10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, Montrasio F, Pattamatta A, Tusi SK, Bardhi O, Meyer KD, Hayes L, Nakamura K, Banez-Coronel M, Coyne A, et al. Antibody therapy targeting RAN proteins rescues C9 ALS/FTD phenotypes in C9orf72 mouse model. Neuron. 2020;105:645&#x2013;662. doi: 10.1016/j.neuron.2019.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.11.007</ArticleId><ArticleId IdType="pmc">PMC7391607</ArticleId><ArticleId IdType="pubmed">31831332</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin KE, Jasin P, Braunstein KE, Sinha I, Bowden KD, Moghekar A, et al. A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. bioRxiv. 2023 2023.2001.2023.525202.</Citation></Reference><Reference><Citation>Seddighi S, Qi YA, Brown A-L, Wilkins OG, Bereda C, Belair C, et al. Mis-spliced transcripts generate de novo&#xa0;proteins in TDP-43-related ALS/FTD. bioRxiv. 2023 2023.2001.2023.525149.</Citation></Reference><Reference><Citation>Iannitelli DE, Tan A, Nguyen E, Babu A, Elorza SD, Joseph T, et al. ALS sensitive spinal motor neurons enter a degenerative downward spiral of impaired splicing and proteostasis. bioRxiv. 2022 2022.2003.2026.485939.</Citation></Reference><Reference><Citation>Heo D, Ling JP, Molina-Castro GC, Langseth AJ, Waisman A, Nave KA, Mobius W, Wong PC, Bergles DE. Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43. Elife. 2022;11:e75230. doi: 10.7554/eLife.75230.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.75230</ArticleId><ArticleId IdType="pmc">PMC8970587</ArticleId><ArticleId IdType="pubmed">35311646</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Arai K, Del Tredici K, Toledo JB, Robinson JL, Lee EB, Kuwabara S, Shibuya K, Irwin DJ, Fang L, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128:423&#x2013;437. doi: 10.1007/s00401-014-1299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1299-6</ArticleId><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohan Z, Matej R, Rusina R, Kovacs GG. Oligodendroglial response in the spinal cord in TDP-43 proteinopathy with motor neuron involvement. Neurodegener Dis. 2014;14:117&#x2013;124. doi: 10.1159/000362929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000362929</ArticleId><ArticleId IdType="pubmed">25115814</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Gentile F, Cerri F, Gallia F, Podini P, Dina G, Falzone YM, Fazio R, Lunetta C, Calvo A, et al. Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain. 2022;145:276&#x2013;284. doi: 10.1093/brain/awab285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab285</ArticleId><ArticleId IdType="pmc">PMC8967102</ArticleId><ArticleId IdType="pubmed">35076694</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattle SB, O'Shaughnessy J, Kantelberg O, Rifai OM, Pate J, Nellany K, Hays N, Arends MJ, Horrocks MH, Waldron FM, Gregory JM. pTDP-43 aggregates accumulate in non-central nervous system tissues prior to symptom onset in amyotrophic lateral sclerosis: a case series linking archival surgical biopsies with clinical phenotypic data. J Pathol Clin Res. 2022;9(1):44&#x2013;55. doi: 10.1002/cjp2.297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cjp2.297</ArticleId><ArticleId IdType="pmc">PMC9732680</ArticleId><ArticleId IdType="pubmed">36226890</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A, Pribadi M, Phillips JJ, Gaus SE, Hixson JD, et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016;139:3202&#x2013;3216. doi: 10.1093/brain/aww250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww250</ArticleId><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez ER, Borschel WF, Traynor BJ. New antisense oligonucleotide therapies reach first base in ALS. Nat Med. 2022;28:25&#x2013;27. doi: 10.1038/s41591-021-01629-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01629-7</ArticleId><ArticleId IdType="pubmed">35075291</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra San Juan I, Nash LA, Smith KS, Leyton-Jaimes MF, Qian M, Klim JR, Limone F, Dorr AB, Couto A, Pintacuda G, et al. Loss of mouse Stmn2 function causes motor neuropathy. Neuron. 2022;110:1671&#x2013;1688. doi: 10.1016/j.neuron.2022.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.02.011</ArticleId><ArticleId IdType="pmc">PMC9119928</ArticleId><ArticleId IdType="pubmed">35294901</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Alstyne M, Tattoli I, Delestree N, Recinos Y, Workman E, Shihabuddin LS, Zhang C, Mentis GZ, Pellizzoni L. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24:930&#x2013;940. doi: 10.1038/s41593-021-00827-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00827-3</ArticleId><ArticleId IdType="pmc">PMC8254787</ArticleId><ArticleId IdType="pubmed">33795885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:53. doi: 10.1038/s41392-021-00487-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00487-6</ArticleId><ArticleId IdType="pmc">PMC7868676</ArticleId><ArticleId IdType="pubmed">33558455</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chio A, Van Damme P, Ludolph AC, Glass JD, et al. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis [https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results].</Citation></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723&#x2013;1732. doi: 10.1056/NEJMoa1702752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed YY. Eteplirsen: first global approval. Drugs. 2016;76:1699&#x2013;1704. doi: 10.1007/s40265-016-0657-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-016-0657-1</ArticleId><ArticleId IdType="pubmed">27807823</ArticleId></ArticleIdList></Reference><Reference><Citation>Eser G, Topaloglu H. Current outline of exon skipping trials in Duchenne muscular dystrophy. Genes (Basel) 2022;13:1241. doi: 10.3390/genes13071241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13071241</ArticleId><ArticleId IdType="pmc">PMC9320322</ArticleId><ArticleId IdType="pubmed">35886024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D. Promise of nucleic acid therapeutics for amyotrophic lateral sclerosis. Ann Neurol. 2022;91:13&#x2013;20. doi: 10.1002/ana.26259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26259</ArticleId><ArticleId IdType="pubmed">34704267</ArticleId></ArticleIdList></Reference><Reference><Citation>Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell. 2018;173:665&#x2013;676. doi: 10.1016/j.cell.2018.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.02.033</ArticleId><ArticleId IdType="pmc">PMC5910255</ArticleId><ArticleId IdType="pubmed">29551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadgil A, Raczynska KD. U7 snRNA: a tool for gene therapy. J Gene Med. 2021;23:e3321. doi: 10.1002/jgm.3321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgm.3321</ArticleId><ArticleId IdType="pmc">PMC8243935</ArticleId><ArticleId IdType="pubmed">33590603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesman D, Rodriguez Y, Rajakumar D, Wein N. U7 snRNA, a small RNA with a big impact in gene therapy. Hum Gene Ther. 2021;32:1317&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">34139889</ArticleId></ArticleIdList></Reference><Reference><Citation>Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, Ling KK, Karp GM, Qi H, Woll MG, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345:688&#x2013;693. doi: 10.1126/science.1250127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1250127</ArticleId><ArticleId IdType="pubmed">25104390</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner KD, Hajdin CE, Weeks KM. Principles for targeting RNA with drug-like small molecules. Nat Rev Drug Discov. 2018;17:547&#x2013;558. doi: 10.1038/nrd.2018.93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.93</ArticleId><ArticleId IdType="pmc">PMC6420209</ArticleId><ArticleId IdType="pubmed">29977051</ArticleId></ArticleIdList></Reference><Reference><Citation>Darras BT, Masson R, Mazurkiewicz-Beldzinska M, Rose K, Xiong H, Zanoteli E, Baranello G, Bruno C, Vlodavets D, Wang Y, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385:427&#x2013;435. doi: 10.1056/NEJMoa2102047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102047</ArticleId><ArticleId IdType="pubmed">34320287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratni H, Scalco RS, Stephan AH. Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines. ACS Med Chem Lett. 2021;12:874&#x2013;877. doi: 10.1021/acsmedchemlett.0c00659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.0c00659</ArticleId><ArticleId IdType="pmc">PMC8201486</ArticleId><ArticleId IdType="pubmed">34141064</ArticleId></ArticleIdList></Reference><Reference><Citation>QurAlis to Present at H.C. Wainwright BioConnect 2022 Virtual Conference [https://quralis.com/quralis-presents-data-about-stathmin-2-role-in-neuronal-disease-biology-and-tdp-43-biomarker-identification-at-ad-pd-2022/].</Citation></Reference><Reference><Citation>Zhu F, Nair RR, Fisher EMC, Cunningham TJ. Humanising the mouse genome piece by piece. Nat Commun. 1845;2019:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6478830</ArticleId><ArticleId IdType="pubmed">31015419</ArticleId></ArticleIdList></Reference><Reference><Citation>The Jackson Laboratory. C57BL/6J-Stmn2em6(STMN2)Lutzy/Mmjax [https://www.jax.org/strain/034061].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>